The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ARCHIVE
ARCHIVE
- DSP, CiRA to Jointly Develop Drugs for a Rare, Intractable Disease
May 16, 2011
- MatsumotoKiyoshi HD Maintains “A-”Rating: R&I
May 16, 2011
- New Dosage Approved for Shionogi's Finibax
May 16, 2011
- Astellas Announces Changes in Top Leadership
May 16, 2011
- Assessing Contamination Risk Important in Wake of Nuclear Accident: Mr Igari of JPMA
May 16, 2011
- Takeda Submits 2 sNDAs for Velcade in the US
May 16, 2011
- Expectations High for BI Japan's Prazaxa, 1st Novel Oral Anticoagulant in Half a Century
May 16, 2011
- Japan Is Best Positioned to Help China Strengthen Its New Drug Development Capability: Mr Hasegawa
May 16, 2011
- Chugai Files for Add'l Indication for Herceptin Based in Info in Public Domain
May 16, 2011
- MSs from Wholesalers Provide Valuable Services in Emergency, MRs Feel Small
May 16, 2011
- Japanese Economy Threatened by “Serious Illness” New Keizai Doyukai Chairman Mr Hasegawa
May 16, 2011
- Actemra Approved for SJIA as Additional Indication in US
May 16, 2011
- Drug Makers to Continue Production through Golden Week
May 16, 2011
- Liovel, Nexium Recommended for Approval
May 16, 2011
- CHMP Gives Positive Opinion for Avastin, Xeloda Combination: Roche
May 16, 2011
- METI to Subsidize Installation of In-house Power Generators
May 16, 2011
- Simponi Recommended for Approval
May 16, 2011
- FDA Issues Complete Response Letter for Aricept Patch: Eisai
May 16, 2011
- Major Drugstore Chains to Hire More New Graduates from Disaster Areas
May 16, 2011
- Kyowa Kirin Files NDA for Anti-CCR4 Antibody KW-0761
May 16, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…